The Managed Care Review Board™ — Analyzing the Latest Advancements for the Treatment of Chronic Myelogenous Leukemia Web Activity

• Release date: February 5, 2016
• Expiration date: August 31, 2017
• Estimated Time to Complete Activity: 1.5 hours
• Compatible with all modern browsers and mobile devices

Distinguished Faculty

Jeffrey D. Dunn, PharmD, MBA Senior Vice President Chief Clinical Officer VRx Pharmacy Services, LLC Click here for biography Christopher Fausel, PharmD, BCPS, BCOP Clinical Manager, Oncology Pharmacy Clinical Pharmacist, Hematology-Oncology-BMT Indiana University Simon Cancer Center Indiana University Health Click here for biography Elias Jabbour, MD Associate Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Click here for biography Fadia T. Shaya, PhD, MPH Professor and Vice-Chair for Academic Affairs University of Maryland School of Pharmacy Click here for biography

Target Audience

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for chronic myelogenous leukemia (CML) including: physicians, pharmacists, registered nurses, and case managers

Statement of Need/Program Overview 
Hematologists, nurses, and oncology pharmacists who care for patients with hematologic malignancies are challenged with determining appropriate treatment sequences and combinations, and obtaining treatment coverage and reimbursement. Given the rising costs of cancer care, these health care professionals must appreciate not only new products’ clinical data and role; they must also be cognizant of the financial consequences of their cancer care recommendations. Because they are responsible for evaluating coverage and reimbursement decisions, managed care personnel also need a solid understanding of clinical data supporting the use of targeted cancer agents, as well as data regarding the integration of these agents into hematologists’ clinical practices.

Educational Objectives
After completing this activity, the participant should be better able to:

• Characterize the benefits of regular and ongoing hematologic and cytogenetic analyses in the management of CML as a means of adjusting treatment plans and maintaining the most appropriate and effective therapy for all patients at all times
• Promote benefit design structures that allow for liberal but judicious use of hematologic and cytogenetic analyses on the part of clinicians treating patients with CML in addition to coverage parameters that integrate the results of said analyses in choosing the most appropriate therapy
• Facilitate a care partnership by providing complete, accurate, and understandable counsel to patients with CML—including information on emerging/investigational therapies and clinical trials of existing agents in novel treatment settings—as part of the managed care and hematology/oncology treatment team
• Integrate innovative oncology pharmacy benefit models and specialty pharmacy management services for oral TKI therapies that enhance accessibility and promote medication adherence
• Further encourage medication persistence with oral TKI therapies by implementing prescription logs/medication diaries to thoroughly monitor drug utilization and aggressively manage toxicities
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

ACCREDITATION

Physician Continuing Medical Education

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Pharmacist Accreditation Statement  Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number –0809-9999-16-084-H01-P)

Type of Activity
Application

Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Nursing Continuing Education

Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Nursing Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period February 5, 2016 through August 31, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.